BridgeMD
Study on the influence of FLUMAzenil regarding the incidence of pediatric emergence delirium (ED) in children undergoing ENT surgery – FLUMA Study
EU CTIS ID: 2025-523543-36-00
What this study is testing
The FLUMA Study will examine the occurrence of pediatric emergence delirium in children following ENT surgery after antagonisation of the sedative effect of Midazolam (Dormicum®) by Flumazenil®.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Children aged 3-7
- ASA status I and II
- ENT anesthesia, regardless of the procedure
- Consent of the legal guardian
- Sufficient language skills in German
You likely can't join if
- ASA status III or IV
- Lack of consent from the legal guardian
- Contraindications for the use of benzodiazepines or flumazenil
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.